Fortrea Holdings Inc. (NASDAQ: FTRE)

Fortrea Holdings Inc. is a leading global contract research organization providing biopharmaceutical product and medical device development solutions. The company offers phase I through IV clinical trial management, clinical pharmacology, and consulting services to pharmaceutical, biotechnology, and medical device customers. With more than 30 years of experience, Fortrea has supported clients across more than 20 therapeutic areas. The firm operates in approximately 100 countries and employs about 14,300 staff worldwide. Its service portfolio includes full service, functional service provider, and hybrid delivery models that can be tailored to the needs of both large and small sponsors.

Fortrea generates revenue by delivering clinical research services under three main delivery models: full service, functional service provider, and hybrid. The full service model integrates multiple disciplines such as protocol design, site selection, patient recruitment, project management, monitoring, data management, and medical writing to support customers from early phase through commercialization. The functional service provider model supplies specialized personnel for discrete tasks including clinical data management, biostatistics, statistical programming, pharmacovigilance, and medical writing, allowing customers to retain control over other study components. The hybrid model combines elements of both approaches to provide efficiencies for large portfolios with similar therapeutic profiles. In addition, the company earns fees from its dedicated clinical research units located in the United Kingdom and the United States, which conduct first in human and early phase studies. Revenue is recognized as services are performed and is generally tied to milestones or fee for service arrangements.

The company operates through the following segments.

• Clinical Services: This segment provides phase I through IV clinical trial management, clinical pharmacology, and consulting services using full service, functional service provider, and hybrid delivery models to support drug and medical device development, operates a network of clinical research units in Leeds, Dallas, Daytona, and Madison, offers expertise in therapeutic areas such as oncology, neurology, metabolism, immunology, cardiovascular, renal, rare diseases, and cell and gene therapy, and leverages data analytics, artificial intelligence, and decentralized trial technologies to improve study efficiency and patient outcomes.

Fortrea holds a strong position in the contract research industry due to its global scale, deep therapeutic expertise, and flexible delivery options. The company competes with other large full service contract research organizations as well as many niche specialists. Its competitive advantages include a presence in approximately 100 countries, a workforce of about 14,300 employees, and experience across more than 20 therapeutic areas. Fortrea’s focus on high growth areas such as oncology, neuroscience, and metabolic disease helps it capture a share of the expanding outsourcing market. The contract research outsourcing market is projected to reach about $145,000,000,000 by 2026, giving the company a sizable addressable opportunity.

Fortrea serves pharmaceutical, biotechnology, and medical device companies ranging from large multinational firms to emerging biotech startups. In fiscal 2025, one customer accounted for approximately 18.1% of revenue while 56% of revenue came from leading pharmaceutical customers. The top 20 customers represented about 69% of total revenue in the same year. The company maintains long term relationships with many clients, often providing multiple services such as clinical trial management, pharmacology, and consulting over several years. Geographic diversification is evident with work performed in North America, Europe, Asia Pacific, and Latin America.